Gross Profit Comparison: Takeda Pharmaceutical Company Limited and Travere Therapeutics, Inc. Trends

Takeda vs. Travere: A Decade of Financial Divergence

__timestampTakeda Pharmaceutical Company LimitedTravere Therapeutics, Inc.
Wednesday, January 1, 2014125683400000027632226
Thursday, January 1, 2015127197300000097707000
Friday, January 1, 20161173296000000129037000
Sunday, January 1, 20171274610000000151332000
Monday, January 1, 20181437534000000158719000
Tuesday, January 1, 20192201424000000170104000
Wednesday, January 1, 20202203504000000192195000
Friday, January 1, 20212462160000000220706000
Saturday, January 1, 20222783406000000204426000
Sunday, January 1, 20232832257000000133788000
Monday, January 1, 20242832257000000
Loading chart...

Data in motion

A Tale of Two Companies: Takeda vs. Travere

In the ever-evolving pharmaceutical industry, the financial trajectories of Takeda Pharmaceutical Company Limited and Travere Therapeutics, Inc. offer a fascinating study in contrasts. Over the past decade, Takeda has demonstrated a robust growth in gross profit, surging by approximately 125% from 2014 to 2023. This Japanese giant's financial prowess is evident, with its gross profit peaking at over 2.8 trillion yen in 2023.

Conversely, Travere Therapeutics, a smaller player in the field, has shown a more modest growth trajectory. From 2014 to 2022, Travere's gross profit increased by nearly 640%, albeit from a much smaller base. However, 2023 saw a decline, highlighting the volatility smaller companies often face.

This comparison underscores the diverse challenges and opportunities within the pharmaceutical sector, where scale and innovation play pivotal roles in shaping financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025